CliffBio
small molecule

TPOXX

TECOVIRIMAT

Loss of exclusivityAugust 2032latest FDA-listed patent expiry
CompanySIGA Technologies →See this company's full patent-cliff portfolio

Drug detail

Brand nameTPOXX
Active ingredientTECOVIRIMAT
Strength200MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

Listed patents

PatentExpiresType
11890270August 2032use U-2346
7737168September 2031use U-2346
9339466March 2031substance, product
12433868March 2031product
8039504July 2027product

More from SIGA Technologies

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TPOXX patent cliff — loss of exclusivity August 2032 | CliffBio